Liminatus Pharma, Inc.
LIMNHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeLiminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. At a $4.9M market cap, Liminatus Pharma, Inc. ranks as a micro-cap company within healthcare. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Market Cap
$4.9M
Beta
0.71
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-24.00
EPS (Fwd)
—
ROE
—
ROA
-95.7%
Cash
$3.0M
Total Debt
$1.4M
Free CF
-$10.0M
52W Change
-96.3%
Annual Financials
Cash vs Debt
Where LIMN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, LIMN finished 67.10% below its 150-day moving average ($11.67) and 79.75% below its 200-day moving average ($18.96). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LIMN overbought or oversold?
At the September 3, 2026 close, LIMN's RSI(14) was 6.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Liminatus Pharma, Inc. holds $3.0M in cash against $1.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$10.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
With cash comfortably exceeding debt, LIMN has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Liminatus Pharma, Inc. and its sector.